ADBRY
ADBRY (tralokinumab) is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis. It is approved for use in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The medication may be administered with or without the concurrent use of topical corticosteroids.
How ADBRY Works
Tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to the cytokine interleukin-13 (IL-13) to inhibit its interaction with the IL-13 receptor α1 and α2 subunits. By blocking the interaction with the IL-13Rα1/IL-4Rα receptor complex, the drug suppresses the bioactivity of the Type 2 immune response. This action inhibits IL-13-induced responses, including the release of proinflammatory cytokines, chemokines, and IgE.
Details
- Status
- Prescription
- First Approved
- 2021-12-27
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ADBRY Approval History
What ADBRY Treats
1 indicationsADBRY is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Atopic Dermatitis
ADBRY Competitors
Pro1 other drug also targets IL-13. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (IL-13). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to ADBRY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ADBRY FDA Label Details
ProIndications & Usage
FDA Label (PDF)ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ADBRY is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.